Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Autoantibodies Against C3b-Functional Consequences and Disease Relevance.

Vasilev VV, Radanova M, Lazarov VJ, Dragon-Durey MA, Fremeaux-Bacchi V, Roumenina LT.

Front Immunol. 2019 Jan 29;10:64. doi: 10.3389/fimmu.2019.00064. eCollection 2019. Review.

2.

Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria.

Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey MA.

Front Immunol. 2018 Dec 14;9:2971. doi: 10.3389/fimmu.2018.02971. eCollection 2018.

3.

Detection of Autoantibodies to Complement Components by Surface Plasmon Resonance-Based Technology.

Noe R, Chauvet S, Togarsimalemath SK, Marinozzi MC, Radanova M, Vasilev VV, Fremeaux-Bacchi V, Dragon-Durey MA, Roumenina LT.

Methods Mol Biol. 2019;1901:271-280. doi: 10.1007/978-1-4939-8949-2_24.

PMID:
30539587
4.

Anti-factor H Autoantibodies Assay by ELISA.

Sénant M, Dragon-Durey MA.

Methods Mol Biol. 2019;1901:191-196. doi: 10.1007/978-1-4939-8949-2_15.

PMID:
30539578
5.

Analytical validation of an alternative method to quantify specific antibodies in 3 applications.

Senant M, Bordereau P, Tartour E, Dragon-Durey MA.

J Immunol Methods. 2019 Jan;464:40-46. doi: 10.1016/j.jim.2018.10.008. Epub 2018 Oct 18.

PMID:
30342009
6.

Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.

Chauvet S, Roumenina LT, Aucouturier P, Marinozzi MC, Dragon-Durey MA, Karras A, Delmas Y, Le Quintrec M, Guerrot D, Jourde-Chiche N, Ribes D, Ronco P, Bridoux F, Fremeaux-Bacchi V.

Front Immunol. 2018 Oct 2;9:2260. doi: 10.3389/fimmu.2018.02260. eCollection 2018.

7.

Gastrointestinal pathogens in anti-FH antibody positive and negative Hemolytic Uremic Syndrome.

Togarsimalemath SK, Si-Mohammed A, Puraswani M, Gupta A, Vabret A, Liguori S, Mariani-Kurkdjian P, Bagga A, Dragon-Durey MA.

Pediatr Res. 2018 Jul;84(1):118-124. doi: 10.1038/s41390-018-0009-9. Epub 2018 May 23.

PMID:
29795200
8.

Routinely used immunoassays do not detect circulating anti-GBM antibodies against native NC1 hexamer and EA epitope of the α3 chain of type IV collagen.

Clavarino G, Gauthier A, Hellmark T, Carron PL, Giovannini D, Colliard S, Dragon-Durey MA, Segelmark M, Cesbron JY, Dumestre-Pérard C.

Eur J Immunol. 2018 Jun;48(6):1082-1084. doi: 10.1002/eji.201747324. Epub 2018 May 2.

PMID:
29644627
9.

Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report.

Deshayes S, Martin Silva N, Chatelet V, Chantepie S, Le Quintrec M, Comoz F, Bridoux F, Dragon-Durey MA, Aouba A.

Clin Rheumatol. 2018 Apr;37(4):1119-1122. doi: 10.1007/s10067-018-4058-6. Epub 2018 Mar 7. Review.

PMID:
29516279
10.

Testing anti-neutrophil cytoplasmic antibodies (ANCA): analysis of the European EASI survey on the daily practice of the French laboratories.

Dragon-Durey MA, Fabien N, Chyderiotis G, Musset L, Pham BN, Olsson N.

Ann Biol Clin (Paris). 2017 Oct 1;75(5):531-541. doi: 10.1684/abc.2017.1273.

PMID:
28958962
11.

A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.

Togarsimalemath SK, Sethi SK, Duggal R, Le Quintrec M, Jha P, Daniel R, Gonnet F, Bansal S, Roumenina LT, Fremeaux-Bacchi V, Kher V, Dragon-Durey MA.

Kidney Int. 2017 Oct;92(4):876-887. doi: 10.1016/j.kint.2017.04.025. Epub 2017 Jul 18.

PMID:
28729035
12.

C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.

Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, Legendre C, Cailliez M, Deschenes G, Fischbach M, Karras A, Nobili F, Pietrement C, Dragon-Durey MA, Fakhouri F, Roumenina LT, Fremeaux-Bacchi V.

Kidney Int. 2017 Nov;92(5):1232-1241. doi: 10.1016/j.kint.2017.04.017. Epub 2017 Jul 14.

PMID:
28712854
13.

Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome.

Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V.

Indian J Nephrol. 2017 Mar-Apr;27(2):136-140. doi: 10.4103/0971-4065.181462.

14.

[Laboratory diagnosis of antiphospholipid syndrome: From criteria to practice].

Joste V, Dragon-Durey MA, Darnige L.

Rev Med Interne. 2018 Jan;39(1):34-41. doi: 10.1016/j.revmed.2017.02.006. Epub 2017 Mar 14. Review. French.

PMID:
28302338
15.

Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced.

Sethi SK, Rohatgi S, Dragon-Durey MA, Raghunathan V, Dhaliwal M, Rawat A, Jha P, Bansal SB, Raina R, Kher V.

Indian J Nephrol. 2017 Jan-Feb;27(1):58-61. doi: 10.4103/0971-4065.179369.

16.

Auto-immunité et gestion des toxicités des traitements par anti-check point inhibiteurs.

Senant M, Giusti D, Weiss L, Dragon-Durey MA.

Bull Cancer. 2016 Nov;103 Suppl 1:S175-S185. doi: 10.1016/S0007-4551(16)30376-9. French.

PMID:
28057182
17.

Application of Deamidated Gliadin Antibodies in the Follow-Up of Treated Celiac Disease.

de Chaisemartin L, Meatchi T, Malamut G, Fernani-Oukil F, Hosking F, Rault D, Bellery F, Cellier C, Dragon-Durey MA.

PLoS One. 2015 Aug 31;10(8):e0136745. doi: 10.1371/journal.pone.0136745. eCollection 2015.

18.

Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.

Vasilev VV, Noe R, Dragon-Durey MA, Chauvet S, Lazarov VJ, Deliyska BP, Fremeaux-Bacchi V, Dimitrov JD, Roumenina LT.

J Biol Chem. 2015 Oct 16;290(42):25343-55. doi: 10.1074/jbc.M115.647008. Epub 2015 Aug 5.

19.

Increased Performances of the Biological Diagnosis of the Antiphospholipid Syndrome by the Use of a Multiplex Assay.

Sénant M, Rostane H, Fernani-Oukil F, Hosking F, Bellery F, Courchinoux A, Tartour E, Darnige L, Dragon-Durey MA.

J Immunol Res. 2015;2015:983094. doi: 10.1155/2015/983094. Epub 2015 May 6.

20.

Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.

Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA.

J Immunol. 2015 Jun 1;194(11):5129-38. doi: 10.4049/jimmunol.1402770. Epub 2015 Apr 27.

21.

Atypical aHUS: State of the art.

Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ.

Mol Immunol. 2015 Sep;67(1):31-42. doi: 10.1016/j.molimm.2015.03.246. Epub 2015 Apr 3. Review.

PMID:
25843230
22.

A case of C3 glomerulonephritis successfully treated with eculizumab.

Payette A, Patey N, Dragon-Durey MA, Frémeaux-Bacchi V, Le Deist F, Lapeyraque AL.

Pediatr Nephrol. 2015 Jun;30(6):1033-7. doi: 10.1007/s00467-015-3061-2. Epub 2015 Mar 22.

PMID:
25796589
23.

Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome.

Khandelwal P, Gupta A, Sinha A, Saini S, Hari P, Dragon Durey MA, Bagga A.

Pediatr Nephrol. 2015 Mar;30(3):451-7. doi: 10.1007/s00467-014-2948-7. Epub 2014 Sep 13.

PMID:
25217328
24.

Inhibition of the mTORC pathway in the antiphospholipid syndrome.

Canaud G, Bienaimé F, Tabarin F, Bataillon G, Seilhean D, Noël LH, Dragon-Durey MA, Snanoudj R, Friedlander G, Halbwachs-Mecarelli L, Legendre C, Terzi F.

N Engl J Med. 2014 Jul 24;371(4):303-12. doi: 10.1056/NEJMoa1312890.

25.

[Complement deficiencies and human diseases].

Rosain J, Ngo S, Bordereau P, Poulain N, Roncelin S, Vieira Martins P, Dragon-Durey MA, Frémeaux-Bacchi V.

Ann Biol Clin (Paris). 2014 May-Jun;72(3):271-80. doi: 10.1684/abc.2014.0961. Review. French.

26.

Therapy for patients with antibodies to complement factor H associated HUS.

Bagga A, Sinha A, Dragon-Durey MA.

Pediatr Nephrol. 2014 May;29(5):939-40. doi: 10.1007/s00467-013-2729-8. Epub 2014 Jan 22. No abstract available.

PMID:
24448737
27.

Anti-factor H autoantibodies assay.

Dragon-Durey MA, Blanc C, Roumenina LT, Poulain N, Ngo S, Bordereau P, Frémeaux-Bacchi V.

Methods Mol Biol. 2014;1100:249-56. doi: 10.1007/978-1-62703-724-2_20.

PMID:
24218265
28.

Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).

Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-Durey MA, Frémeaux-Bacchi V.

Methods Mol Biol. 2014;1100:237-47. doi: 10.1007/978-1-62703-724-2_19.

PMID:
24218264
29.

Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.

Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, Bagga A; Indian HUS Registry.

Kidney Int. 2014 May;85(5):1151-60. doi: 10.1038/ki.2013.373. Epub 2013 Oct 2.

30.

Standardisation of the factor H autoantibody assay.

Watson R, Lindner S, Bordereau P, Hunze EM, Tak F, Ngo S, Zipfel PF, Skerka C, Dragon-Durey MA, Marchbank KJ.

Immunobiology. 2014 Jan;219(1):9-16. doi: 10.1016/j.imbio.2013.06.004. Epub 2013 Jun 26.

PMID:
23891327
31.

Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.

Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouvière C, Bérard E, Salomon R, Frémeaux-Bacchi V, Niaudet P, Boyer O.

Pediatr Nephrol. 2014 Jan;29(1):75-83. doi: 10.1007/s00467-013-2558-9. Epub 2013 Jul 19.

PMID:
23868108
32.

Autoantibodies against complement components and functional consequences.

Dragon-Durey MA, Blanc C, Marinozzi MC, van Schaarenburg RA, Trouw LA.

Mol Immunol. 2013 Dec 15;56(3):213-21. doi: 10.1016/j.molimm.2013.05.009. Epub 2013 Jun 20. Review.

PMID:
23790637
33.

An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.

Hebecker M, Alba-Domínguez M, Roumenina LT, Reuter S, Hyvärinen S, Dragon-Durey MA, Jokiranta TS, Sánchez-Corral P, Józsi M.

J Immunol. 2013 Jul 15;191(2):912-21. doi: 10.4049/jimmunol.1300269. Epub 2013 Jun 14.

34.

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C.

Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62. doi: 10.2215/CJN.04760512. Epub 2013 Jan 10.

35.

Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.

Blanc C, Roumenina LT, Ashraf Y, Hyvärinen S, Sethi SK, Ranchin B, Niaudet P, Loirat C, Gulati A, Bagga A, Fridman WH, Sautès-Fridman C, Jokiranta TS, Frémeaux-Bacchi V, Dragon-Durey MA.

J Immunol. 2012 Oct 1;189(7):3528-37. Epub 2012 Aug 24.

36.

Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.

Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V.

Kidney Int. 2012 Aug;82(4):454-64. doi: 10.1038/ki.2012.63. Epub 2012 Mar 28.

37.

Genetics of hemolytic uremic syndromes.

Malina M, Roumenina LT, Seeman T, Le Quintrec M, Dragon-Durey MA, Schaefer F, Fremeaux-Bacchi V.

Presse Med. 2012 Mar;41(3 Pt 2):e105-14. doi: 10.1016/j.lpm.2011.10.028. Epub 2012 Jan 20. Review.

PMID:
22265161
38.

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.

Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, Bigot S, Hue C, Satchell SC, Mathieson PW, Mousson C, Noel C, Sautes-Fridman C, Halbwachs-Mecarelli L, Atkinson JP, Lionet A, Fremeaux-Bacchi V.

Blood. 2012 May 3;119(18):4182-91. doi: 10.1182/blood-2011-10-383281. Epub 2012 Jan 13.

39.

Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance.

Roumenina LT, Sène D, Radanova M, Blouin J, Halbwachs-Mecarelli L, Dragon-Durey MA, Fridman WH, Fremeaux-Bacchi V.

J Immunol. 2011 Oct 15;187(8):4369-73. doi: 10.4049/jimmunol.1101749. Epub 2011 Sep 19.

40.

Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study.

Ghillani P, André C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, Goulvestre C, Gleizes A, Dragon-Durey MA, Alyanakian MA, Chretien P, Chollet-Martin S, Musset L, Weill B, Johanet C.

Autoimmun Rev. 2011 Jul;10(9):509-13. doi: 10.1016/j.autrev.2011.03.004. Epub 2011 Apr 5.

PMID:
21447407
41.

Heterogeneous pattern of renal disease associated with homozygous factor H deficiency.

Servais A, Noël LH, Dragon-Durey MA, Gübler MC, Rémy P, Buob D, Cordonnier C, Makdassi R, Jaber W, Boulanger E, Lesavre P, Frémeaux-Bacchi V.

Hum Pathol. 2011 Sep;42(9):1305-11. doi: 10.1016/j.humpath.2010.11.023. Epub 2011 Mar 10.

PMID:
21396679
42.

[Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].

Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C.

Rev Med Interne. 2011 Apr;32(4):232-40. doi: 10.1016/j.revmed.2009.09.039. Epub 2011 Mar 3. French.

43.

Alternative complement pathway assessment in patients with atypical HUS.

Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V.

J Immunol Methods. 2011 Feb 28;365(1-2):8-26. doi: 10.1016/j.jim.2010.12.020. Epub 2011 Jan 6. Review.

PMID:
21215749
44.

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.

Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V.

J Am Soc Nephrol. 2010 Dec;21(12):2180-7. doi: 10.1681/ASN.2010030315. Epub 2010 Nov 4.

45.

Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.

Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB.

Semin Thromb Hemost. 2010 Sep;36(6):633-40. doi: 10.1055/s-0030-1262885. Epub 2010 Sep 23. Review.

PMID:
20865640
46.

Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey MA, Bridoux F, Rondeau E, Frémeaux-Bacchi V.

J Am Soc Nephrol. 2010 May;21(5):859-67. doi: 10.1681/ASN.2009070706. Epub 2010 Mar 4.

47.

Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.

Boyer O, Balzamo E, Charbit M, Biebuyck-Gougé N, Salomon R, Dragon-Durey MA, Frémeaux-Bacchi V, Niaudet P.

Am J Kidney Dis. 2010 May;55(5):923-7. doi: 10.1053/j.ajkd.2009.12.026. Epub 2010 Mar 3.

PMID:
20202729
48.

Lupus nephritis associated with complete C1s deficiency efficiently treated with rituximab: a case report.

Bienaimé F, Quartier P, Dragon-Durey MA, Frémeaux-Bacchi V, Bader-Meunier B, Patey N, Salomon R, Noël LH.

Arthritis Care Res (Hoboken). 2010 Sep;62(9):1346-50. doi: 10.1002/acr.20163. No abstract available.

49.

Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.

Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautés-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V.

Kidney Int. 2010 Feb;77(4):339-49. doi: 10.1038/ki.2009.472. Epub 2009 Dec 16.

50.

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.

Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulonguet L, Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V.

Blood. 2009 Sep 24;114(13):2837-45. doi: 10.1182/blood-2009-01-197640. Epub 2009 Jul 7.

Supplemental Content

Loading ...
Support Center